You will be shown an abstract from a biomedical research paper. Given this abstract, your task is to extract all unique entities of the following types: ["Outcome", "Participant", "Intervention"].

Please return the output as a JSON object of the format: {"Participant" : ["patients with COPD", ...], "Intervention" : ["Atenolol", ...], "Outcome" : ["blood pressure", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

Granulocyte-macrophage colony-stimulating factor ( GM-CSF ) allows acceleration and dose intensity increase of CEF chemotherapy : a randomised study in patients with advanced breast cancer . A randomised study was conducted in 62 patients with advanced breast cancer to assess whether granulocyte-macrophage colony-stimulating factor ( GM-CSF ) would yield an increase in the dose intensity of a standard-dose CEF regimen through an acceleration of chemotherapy administration . Patients received CEF ( cyclophosphamide 600 mg m-2 , epidoxorubicin 60 mg m-2 and fluorouracil 600 mg m-2 ) i.v . on day 1 or the same chemotherapy , plus GM-CSF 10 micrograms kg-1 s.c. starting from day 4 , repeated as soon as haematopoietic recovery from nadir occurred . Patients in the CEF + GM-CSF group received chemotherapy at a median interval of 16 days compared with 20 days in the control group . This led to a significant increase ( P = 0.02 ) in the dose intensity actually administered in the third , fourth and sixth cycles : +28 % , +25 % , +20 % respectively . Non-haematological toxicity was mild . GM-CSF had to be reduced or suspended in 50 % of patients because of toxicity . Haematological toxicity , mainly cumulative anaemia and thrombocytopenia , was manageable . An increase in response rate for patients with measurable disease , of borderline statistical significance ( P = 0.088 , P for trend = 0.018 ) , from 42 % in the CEF group to 69 % in the CEF + GM-CSF group , was observed . This randomised trial indicates that GM-CSF is useful for chemotherapy acceleration . Accelerated CEF + GM-CSF is a moderately dose-intensive regimen that can be administered in an outpatient clinic and is associated with a high objective response .
{"Intervention": ["fluorouracil 600 mg m-2", "cyclophosphamide 600 mg m-2", "CEF", "standard-dose CEF regimen", "Granulocyte-macrophage colony-stimulating factor ( GM-CSF )", "GM-CSF", "chemotherapy", "epidoxorubicin 60 mg m-2", "CEF + GM-CSF", "CEF chemotherapy"], "Outcome": ["Haematological toxicity", "cumulative anaemia and thrombocytopenia", "response rate", "toxicity", "Non-haematological toxicity"], "Participant": ["62", "patients with advanced breast cancer .", "patients with advanced breast cancer"]}